SECTOR: HEALTHCARE
MOTIF BIO
(MTFB.L)
SECTOR – HEALTHCARE
RATING – BUY*
MARKET CAP – £90.7m
CURRENT PRICE – 30.6p#
ANALYST: VADIM ALEXANDRE
Year-end Dec
2016A
2017A
2018E
2019E
Revenue (£m)
-
-
EBITDA (£m)
(39.71)
(38.02)
Adj. pre-tax Profit (£m)
(40.32)
(44.79)
Adj. EPS (p)
(34.60)
(19.35)
Under
review
DPS (p)
-
-
Net Cash/(Debt) (£m)
15.53
(4.53)
P/E (x)
-
-
Dividend yield (%)
-
-
EV/EBITDA (x)
-
-
SOURCE: Northland Capital Partners Limited estimates. #Priced at prior trading day close. *Northland Capital Partners Limited acts as Joint Broker to Motif Bio and therefore this information should be viewed as a Marketing Communication.
Motif Bio to present at Jefferies Global Healthcare Conference in New York
NORTHLAND VIEW
- Motif Bio will present at the Jefferies Global Healthcare Conference in New York on June 8th 2018.
- The conference will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.
The conference presents an opportunity for the Company to interact with a range of healthcare companies and potential partners. In early Q2 2018, Motif initiated an NDA rolling submission with the FDA, regarding the use of iclaprim for acute bacterial skin and skin structure infections (ABSSSI) in the US, and we expect an approval decision before the end of Q1 2019.
COMPANY DESCRIPTION
Clinical stage biopharmaceutical company specialising in the development of novel antibiotics.
POLAREAN IMAGING (POLX.L)
SECTOR – HEALTHCARE
RATING CORP*
MARKET CAP – £11m
CURRENT PRICE – 15p#
ANALYST – VADIM ALEXANDRE
Year-end Dec
2017E
2018E
2019E
2020E
No Forecasts Provided
SOURCE: Northland Capital Partners Limited estimates.*Northland Capital Partners Limited provides acts as Nomad and Broker to Polarean Imaging Ltd. and therefore this information should be viewed as a Marketing Communication.
London Investor Symposium
NORTHLAND VIEW
§ Polarean Imaging will host an Investor Symposium in London on Tuesday 19th June 2018.
§ The event will take place at Grace Hall, 147 Leadenhall Street, London, EC3V 4QT, beginning at 8.45am for a 9.00am start.
§ A welcome and introduction will be given by Richard Morgan and Richard Hullihen, Chairman and CEO respectively. The morning will also feature presentations by:
§ Bastiaan Driehuys, Founder and CTO: Overview of the latest scientific and clinical application results
§ Professor Fergus Gleeson, Clinical Adviser Insight into the benefits of Polarean's technology which is used daily at the University of Oxford
§ Kenneth West, COO: The Phase III clinical trial and status
The Symposium will be a good opportunity for investors to meet with the Management and key opinion leaders as well as learning more about Polarean’s novel technology. Listing in March 2018, Polarean Imaging remains the single healthcare IPO on AIM this calendar year. The Company has a late clinical-stage drug-device platform that allows for improved level of lung function imaging using MRI.
To attend please contact Walbrook PR on 020 7933 8780 or email polarean@walbrookpr.com.
COMPANY DESCRIPTION
Polarean Imaging is a healthcare technology company with a proprietary drug-device combination in late-stage clinical trials.